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Objectives: The aim of this study was to make an initial estimation on the 
effects of a sodium bicarbonate and xylitol spray (Cariex®), associated with 
non-surgical periodontal therapy, in participants with primary Sjögren's 
syndrome.  
Background: Sjögren's syndrome (SS) is a multisystem autoimmune disease 
that predominantly involves salivary and lachrymal glands, with the clinical 
effect of dry eyes and mouth. 
Materials and methods: A prospective cohort of 22 females and 2 males has 
been evaluated. They were randomized into three groups (8 patients each): 
Group A) those treated once with non-surgical periodontal therapy, education 
and motivation to oral hygiene, associated with the use of Cariex®; Group B) 
treated only with Cariex®; Group C) treated only with non-surgical periodontal 
therapy, education and motivation to oral hygiene. Clinical variables described 
after treatment were: unstimulated whole salivary flow, stimulated whole 
salivary flow, salivary pH, reported pain (using Visual Analogue Scale), and 
the Periodontal Screening and Recording index.  
Results: Salivary flow rate improved in all groups, but the difference was 
statistically significant only in those treated with Cariex®, alone or in 
combination with periodontal therapy. Gingival status improved in participants 
who underwent periodontal non-surgical therapy while remained unchanged 
in those only treated with Cariex®. Reported pain decreased in all groups, 
showing the best result in participants treated with periodontal therapy 
together with Cariex®. 
Conclusions: We propose a practical approach for improving gingival 
conditions and alleviating oral symptoms in patients with SS. Future 
randomized and controlled trials are however required to confirm these results 
as well as larger population, and also assessing other parameters due to oral 




Sjögren's syndrome (SS) is a multisystem autoimmune disease characterized 
by hypofunction of the salivary and lacrimal glands (1). SS may occur alone 
and is defined as primary SS, or in association with other autoimmune 
diseases therefore it is defined as secondary SS (2). Dysfunction and 
destruction of the exocrine glands (relating also to alterations in secretory 
products) are associated with lymphocytic infiltration and immunological 
hyperactivity, with 88% of SS subjects having a reduced salivary flow rate, 
followed by complaints of xerostomia in the 75 to 92% range. 
The distinctive reduction in saliva production (hyposalivation) is often 
associated with meaningful consequences for oral health. A feeling of a dry 
mouth (xerostomia), difficulty to talk, swallow and eat, difficulty in controlling 
dentures, taste disturbances and burning sensation are among the most 
frequent subjective symptoms reported (3, 4). These symptoms have a 
typically negative impact on the oral health-related quality of life of patients (5, 
6). 
Patients with SS may also have a significantly higher dental plaque 
accumulation if compared to healthy controls (7), leading to many dental and 
gingival problems.  
Glandular manifestations of SS are mostly alleviated with symptomatic 
treatments, - such as saliva substitutes and eye lubricants – and/or 
cholinergic stimulators; the latter however, in association with other different 
systemic therapy usually prescribed, are related to many potential adverse 
effects (8,9).  
The aim of this study was to make a preliminary estimate on the effects of a 
sodium bicarbonate and xylitol spray (Cariex®), associated with non-surgical 
periodontal therapy, on oral discomfort and gingival status of people with 
primary SS.  
 
Materials and methods 
Participants enrolled 
Consecutive Caucasian participants, attending the Oral Medicine Section of 
the CIR - Dental School, University of Turin, Italy, from January to October 
2014, were selected. 
The inclusion criteria were: a) diagnosis of primary SS on the basis of AECG 
criteria (10); b) presence of reported complaint of xerostomia; c) ability to 
complete the present clinical trial. The exclusion criteria were: a) earlier head 
and neck radiotherapy; b) diagnosed lymphoma; c) hepatitis C infection; d) 
pregnant or breast-feeding subjects; e) to have less than 20 natural teeth. 
Different treatment options were discussed with the participants, and they all 
submitted written informed consent before enrolment, which was carried out in 
accordance with the Helsinki declaration. The ethics review board of the CIR - 
Dental School approved the study. 
Clinical recordings 
All participants had their unstimulated whole salivary flow (UWS) measured 
mid-morning, at least two hours after the last food intake; they were asked to 
allow all saliva to drain into a beaker by drooling or gentle spitting; they were 
instructed not to chew, swallow or speak. Saliva was collected for a period of 
15 minutes and the flow expressed in ml/min. Ten minutes later, stimulated 
whole salivary flow (SWS) was measured by dropping citric acid on the 
dorsum of the tongue every 60 seconds (11). 
Permanent dentitions were studied for decayed, missing, and filled teeth 
(DMFT): all teeth with a realistic suspicion of or definitely showing a cavity in 
the dentin layer were assigned to the D component; filled and crowned teeth 
were evaluated as component F; missing teeth were assigned to the M 
component.  
The periodontal condition was assessed with the use of the Periodontal 
Screening and Recording (PSR) index. The examination was performed with 
the World Health Organization probe at six points per tooth and the PSR 
score was recorded using the following criteria: “0” if probing depth (PD) <3.5 
mm, no bleeding on probing (BOP), and no calculus; “1” if PD <3.5 mm, BOP, 
and no calculus; “2” if PD <3.5 mm, BOP, and calculus is present; “3” if PD is 
3.5 to 5.5 mm; and “4” if PD is >5.5 mm. The highest score was determined 
for each sextant of the dentition. Using the PSR scores, the periodontal 
classification was categorized as follows: 1) healthy: maximum one sextant 
score 1 or 2; 2) gingivitis: score 0 to 2, maximum one sextant score 3; 3) 
moderate periodontitis: >1 sextant score 3, maximum one sextant score 4; 
and 4) severe periodontitis: >1 sextant score 4.  
The subjective oral discomfort was assessed by the xerostomia questionnaire 
(XQ-I), a self-administered tool with 8 questions, the sum of which is 
transformed linearly to produce the final summary score ranging from 0 to 
100, with higher scores representing greater levels of xerostomia (12). 
Moreover, the reported pain due to xerostomia was assessed by Visual 
Analogue Scale (VAS), consisting of a 100 mm-vertical line marked with 0 
(=no pain) to 100 (=most severe pain experienced) (13). 
Levels of USW pH were measured using an Oakton ph5/6® pH meter (Eutech 
Instruments Europe B.V., Landsmeer, The Netherlands) with an Hamilton 
Minitrode® electrode. 
The EULAR Sjögren's Syndrome Disease Activity Index (ESS-DAI) was also 
used to score disease activity at baseline (14). 
Experimental design 
The product tested (Cariex®, Brux srl, Cislago, Italy) is a novel mucoadhesive 
spray that contains sodium bicarbonate, xylitol, polyols, hyaluronic acid and 
various excipients. It was used for 89 days. 
The participants were randomized into three groups: Group A) treated once 
with non-surgical periodontal therapy, education and motivation to oral 
hygiene, associated with the use of Cariex®; Group B) treated only with 
Cariex®; Group C) treated only with non-surgical periodontal therapy, 
education and motivation to oral hygiene. 
Allocation to the three different groups was performed by non-clinical staff via 
a permuted random block approach and was concealed in opaque envelopes, 
which were opened on the first visit data collection (T0). 
After every meal (3 times daily), the Cariex® had to be applied three times in 
correspondence with the buccal mucosa of the cheek; then participants had to 
wait 20 minutes before performing standard oral hygiene procedures. 
Group A and C received non-surgical periodontal therapy (once at baseline), 
consisting of supra- and sub-gingival scaling with removal of all deposits and 
staining. They were also instructed about oral hygiene maintenance at home. 
Instr
associated with interdental brushes. Patients were advised to change brushes 
every 4 weeks and to change interdental brushes every 2 weeks. 
The study was single blinded; a skilled single examiner (A.C.) visited 
participants and performed the follow-up visits or clinical measurements at 
baseline (T0), after 30 and 90 days from the procedure (T1-T2) (Table 1). 
Statistical design 
This is a descriptive exploratory study. Sample size was not estimated on the 
lack of any previously reported changes in alleviating xerostomia in SS 
patients by using a sodium bicarbonate and xylitol spray with non-surgical 
periodontal therapy. However, a possible sample size was calculated on a 
supposed overall efficacy of 85% and 35% for both treatments and only one 
respectively; with a power of 80% and a type I error of 0.05, at least 24 
patients had to be recruited. 
The statistical analysis was performed using the Kruskal Wallis Test to assess 
the variability between samples at baseline, the Wilcoxon Signed Ranks Test 
to assess the difference in each group before and after treatment proposed, 
and the Mann-Whitney Test for comparison between the 3 groups at the end 
of therapy. Statistical significance level was set at 0.05. SPSS (SPSS for 




A total of 22 females and 2 males were selected; the average age at 
presentation was 64.58 years. Of the 24 patients with SS, 8 were treated in 
each of the 3 different protocols. 
At baseline, demographical and clinical parameters showed no statistical 
differences in the study population (Table 2). Saliva substitutes were used in 
15 patients (62.5%) (5 patients in each group; P=1). Specific medications for 
SS above all taken by our cohort study population were hydroxychloroquine 
(25%), systemic steroids (20.8%), and methotrexate (4.1%), with no 
differences between groups (data not shown). 
Changing of clinical parameters, before (T0) and after (T2) the proposed 
protocols, are reported in Table 3. Salivary production improved in every 
groups; the differences, however, were statistically significant only in Group A 
and Group B if considering UWS. pH values increased in all groups, but in a 
statistically manner only for those participants not treated with Cariex® (p = 
0.03). Gingival status statistically improved in participants who underwent 
periodontal non-surgical therapy while remained almost unchanged in those 
only treated with Cariex®. Reported pain decreased in all groups, showing the 
best result in participants treated with periodontal therapy together with 
Cariex® (p=0.03). 
Finally, a comparison of gained results between the 3 protocols was made 
(Table 4), reporting few differences. The only statistical data was obtained 
between Group B and Group C: participants treated only with Cariex® did not 
show a better gingival status after the end of the follow-up period.  
None of the patients treated with Cariex® reported any adverse effects. 
 
Discussion 
In this study, we preliminary showed the outcome that the combined use of a 
sodium bicarbonate and xylitol spray (Cariex®), associated with non-surgical 
periodontal therapy, had in patients with SS. Salivary flow rate statistically 
improved only in participants treated with Cariex®, alone or in combination 
with periodontal therapy. Gingival status improved only in those who 
underwent periodontal non-surgical therapy. Reported pain decreased in all 
groups, showing the best result if treated with periodontal therapy together 
with Cariex®. 
Oral symptoms reported are very common among SS patients: feeling of dry 
mouth, difficulty to talk, swallow and eat, difficulty in controlling dentures, taste 
disturbances and burning sensation are among the most frequent. These 
symptoms may have a negative impact on the oral health-related quality of life 
(9). In this study, we only assessed reported pain, but future study must be 
directed to analyse all other parameters. The VAS scale for symptoms 
showed a statistically significant difference at T0 and T2 only for participants 
treated with both protocols (Group A). This may suggest that the synergistic 
action of the sessions of oral hygiene and sodium bicarbonate, applied on the 
oral mucosa, could decrease subjective reported oral pain in patients with SS. 
To date, there are few data focused on the possible correlation between SS 
and periodontal disease, although with some contradiction. One analysis of 
the relative risk of periodontitis showed that the SS group developed 
periodontal disease twice often if compared to the control group (7), but other 
authors did not find any correlations (15). In our study, it is also possible to 
assume that SS patients had a poor gingival and periodontal status. All 
patients in groups A and C were subjected to non-surgical periodontal therapy 
and showed an improvement of PSR at the end of treatment. We also have a 
significant difference of PSR (p = 0.005) between the second and the third 
group; this difference was predictable because in group C non-surgical 
periodontal was performed, unlike group B. No significant difference was 
found between group A and group B; this could be due to the limits of the 
PSR index:  one single site may affect the assessment assigned to the whole 
sextant and could not represent the complete periodontal status of the 
patients (12). 
It has been known for a long time that SS patients have greater susceptibility 
to develop caries and susceptibility to infections (16-18). Particularly, root and 
incisal caries, which are occasionally detected amongst the general 
population, are of greater apprehension for those with SS (19). In healthy 
people with suitable salivary output, bacteria are dislocated from the teeth by 
the mechanical process of chewing, tongue movement and salivary flow; 
however, for those suffering from SS, impaired salivary flow does not permit 
the oral self-cleansing which buffers, lubricates and performs essential 
antimicrobial duties (19-20). Despite the small sample of this study, the data 
obtained are in agreement with these studies. 
To date, sodium bicarbonate has never been tested in patients with SS; few 
reports on its use are present in literature but in healthy subjects and for a 
limited period. It has been reported that a chewing bicarbonate-containing 
gum could have a positive effect on salivary flow rate and in pH (21). More 
recently, the Cariex® spray has been positively tested, showing to control the 
lowering of salivary pH following carbohydrate consumption (22). 
Our exploratory results showed that the sodium-bicarbonate spray could have 
a partial effect and could not affect salivary acidity for a long period; however, 
in combination with periodontal non-surgical therapy, it could be useful in 
controlling oral discomfort for SS patients; moreover, even if the average age 
of participants was in the mid-sixties, it has to be said that this protocol could 
also be useful for younger SS patients. Patients’ related outcome, measured 
with VAS, appeared to be the main indicator supporting the use of Cariex® in 
those patients. 
Subjects who underwent both protocols showed statistically significant 
differences for the salivary flow values, gingival parameters and symptoms 
reported. In terms of clinical evaluation, a change in salivary pH was observed 
in patients after they had been instructed to correct oral hygiene at home and 
were able to maintain a good compliance, as PSR indexes of all groups show: 
in fact, lowering the oral bacteria has contributed to a change of the pH of 
saliva to basic values observed over a period of three months. 
Treatment for SS is symptomatic and supportive; with no adequate amount of 
saliva to give proper oral pH and regulate microbial populations, the mouth 
can rapidly be colonized with more pathogenic microorganisms. A 
personalized treatment plan must be developed and a preventive oral health 
plan should include meticulous oral hygiene instructions to improve the quality 
of life, and avoid further complications (19). 
 
Conclusion 
To the best of our knowledge, similar data have never been reported.  
This exploratory study found possible beneficial effects of a sodium 
bicarbonate and xylitol spray (Cariex®) when combined with non-surgical 
periodontal therapy on oral discomfort and gingival status of people with 
primary SS. However, it seems that the effectiveness of the offered treatment 
had a limited range of action. For this reason, it is essential that SS patients 
undergo regular oral and dental examinations. 
We propose a practical approach for managing the problematic oral health 
conditions in patients with SS, providing possibly measurements that can be 
used to fully test the effectiveness of this or other preventive agents in 
subjects with dry mouth. Future randomized and controlled trials are actually 
required to confirm these results as well as larger population, and also 
assessing other parameters (such as talking, swallowing and eating, 
controlling dentures, taste disturbances and burning sensations), oral 
infections and more comprehensive periodontal indices. 
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